Telomir Pharmaceuticals, Inc.
TELONasdaqCIK 1971532HealthcareFiscal year ends Dec 31
Reports and events: 79 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0608:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045860 |
| 2026-09-1708:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-043053 |
| 2026-09-1616:30 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-042926 |
| 2026-09-1408:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042483 |
| 2026-08-1317:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001493152-26-037854 |
| 2026-08-1008:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036742 |
| 2026-07-2817:00 ET | DEF 14A | Proxy statementPeriod 2026-07-28 | 0001493152-26-035026 |
| 2026-06-1508:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028614 |
| 2026-06-0817:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-027752 |
| 2026-05-2008:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-024517 |
| 2026-05-1415:09 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001493152-26-023010 |
| 2026-04-3008:15 ET | 8-K | 8.01 Other events | 0001493152-26-019773 |
| 2026-04-2409:00 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-018867 |
| 2026-03-3109:15 ET | 8-K | 8.01 Other events | 0001493152-26-013872 |
| 2026-03-3107:00 ET | 8-K | 8.01 Other events | 0001493152-26-013785 |
| 2026-03-2717:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-013240 |
| 2026-03-1717:28 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001493152-26-010625 |
| 2026-02-1708:00 ET | 8-K | 8.01 Other events | 0001493152-26-006937 |
| 2026-02-0507:30 ET | 8-K | 8.01 Other events | 0001493152-26-005199 |
| 2026-01-1219:50 ET | 8-K | 3.01 Delisting notice | 0001493152-26-001170 |
| 2026-01-0508:00 ET | 8-K | 8.01 Other events | 0001493152-26-000267 |
| 2025-12-2220:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001493152-25-028620 |
| 2025-12-1716:01 ET | 8-K | 8.01 Other events | 0001493152-25-028126 |
| 2025-11-2416:01 ET | 8-K | 8.01 Other events | 0001493152-25-024818 |
| 2025-11-2017:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-25-024491 |
| 2025-11-2016:01 ET | 8-K | 8.01 Other events | 0001493152-25-024450 |
| 2025-11-1207:00 ET | 8-K | 8.01 Other events | 0001493152-25-021712 |
| 2025-11-1016:01 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001493152-25-021496 |
| 2025-10-2216:01 ET | 8-K | 8.01 Other events | 0001493152-25-018907 |
| 2025-10-2016:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-25-018634 |
| 2025-10-1407:30 ET | 8-K | 8.01 Other events | 0001493152-25-017916 |
| 2025-10-0816:01 ET | 8-K | 8.01 Other events | 0001493152-25-017422 |
| 2025-10-0616:01 ET | 8-K | 8.01 Other events | 0001493152-25-017072 |
| 2025-09-1807:30 ET | 8-K | 8.01 Other events | 0001493152-25-013970 |
| 2025-09-0907:30 ET | 8-K | 8.01 Other events | 0001641172-25-026931 |
| 2025-09-0410:13 ET | 8-K | 8.01 Other events | 0001641172-25-026527 |
| 2025-08-2716:01 ET | 8-K | 8.01 Other events | 0001641172-25-025688 |
| 2025-08-1416:02 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001641172-25-023970 |
| 2025-08-0707:30 ET | 8-K | 8.01 Other events | 0001641172-25-022506 |
| 2025-07-2316:01 ET | 8-K | 8.01 Other events | 0001641172-25-020687 |
| 2025-07-2216:01 ET | 8-K | 8.01 Other events | 0001641172-25-020563 |
| 2025-07-1716:01 ET | 8-K | 8.01 Other events | 0001641172-25-020042 |
| 2025-06-1809:15 ET | 8-K | 8.01 Other events | 0001641172-25-015522 |
| 2025-06-1109:30 ET | 8-K | 8.01 Other events | 0001641172-25-014648 |
| 2025-06-0508:00 ET | 8-K | 8.01 Other events | 0001641172-25-013711 |
| 2025-06-0208:00 ET | 8-K | 8.01 Other events | 0001641172-25-013196 |
| 2025-05-2908:00 ET | 8-K | 8.01 Other events | 0001641172-25-012785 |
| 2025-05-2117:25 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001641172-25-011938 |
| 2025-05-2108:45 ET | 8-K | 3.02 Unregistered sale of equity; 8.01 Other events | 0001641172-25-011868 |
| 2025-05-1507:45 ET | 8-K | 8.01 Other events | 0001641172-25-010518 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 16:31 ET. Listed shows no prices and gives no investment advice.